Table 1.
Patient characteristics
| Characteristics | Patients (n = 40) n (%) |
|---|---|
| Age (years) | |
| Median | 63.9 |
| Range | 31.7–78.3 |
| Primary tumor size (cm) | |
| Median | 5.0 |
| Range | 1.5–14.0 |
| Tumor stage (FIGO) | |
| I | 0 (0.0) |
| II | 0 (0.0) |
| III | 31 (77.5) |
| IIIa | 0 (0.0) |
| IIIb | 4 (10.0) |
| IIIc | 27 (67.5) |
| IV | 9 (22.5) |
| Nodal status | |
| pN0 | 10 (25.0) |
| pN1 | 13 (32.5) |
| LNE not performed | 17 (42.5) |
| Hormone receptor | |
| ER | |
| Positive | 36 (90.0) |
| Negative | 4 (10.0) |
| PR | |
| Positive | 17 (42.5) |
| Negative | 23 (57.5) |
| p53 | |
| Positive | 36 (90.0) |
| Negative | 3 (7.5) |
| Missing | 1 (2.5) |
| Ki-67 (%) | |
| Median | 50.0 |
| Range | 2.0–80.0 |
| Postoperative residual tumor burden | |
| Yes | 25 (62.5) |
| No | 15 (37.5) |
| Adjuvant chemotherapy | |
| Complete | 27 (67.5) |
| Incomplete | 7 (17.5) |
| Missing | 6 (15.0) |
| Recurrence status | |
| Recurrence | 37 (92.5) |
| Without recurrence | 3 (7.5) |
| Living status | |
| Living | 4 (10.0) |
| Dead | 36 (90.0) |
ER estrogen receptor, FIGO Fédération Internationale de Gynécologie et d’Obstétrique, LNE lymph-node extirpation, PR progesterone receptor